Skip to main content

Matinas BioPharma Holdings, Inc.

MTNB
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001582554

No open-market purchases or sales by Matinas BioPharma Holdings, Inc. insiders were filed in the last 90 days; 25 institutions reported holding it in 13F filings for Q2 2026, worth $199.2K in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Matinas BioPharma Holdings, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of MTNB: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders6656−10
Shares27.1M25.2M−1.91M (−7.0%)
Value$27.4M$20.3M−$7.09M (−25.9%)

New holders (7)

Institutions that held Matinas BioPharma Holdings, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to MTNB in Q1 2022
InstitutionSharesValue% of portfolio
Kingsbury Capital Investment Advisors LLC119,949$96.0K0.11%
Atria Wealth Solutions, Inc.39,400$32.0K0.00%
Jane Street Group, LLC15,511$12.0K0.00%
Kovitz Investment Group Partners, LLC15,000$12.0K0.00%
FMR LLC7,400$6.00K0.00%
Tower Research Capital LLC (TRC)5,607$5.00K0.00%
Lansing Street Advisors750$1.00K0.00%

Sold out (17)

Institutions that held Matinas BioPharma Holdings, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.